홈 > 시장보고서 > 의약품 > 바이오의약품

시장보고서

상품코드

1422166

플라스미드 DNA 제조 시장 : 성장, 전망, 경쟁 분석(2023-2031년)

Plasmid DNA Manufacturing Market - Growth, Future Prospects and Competitive Analysis, 2023 - 2031

발행일: 2024년 01월 | 리서치사:

Acute Market Reports | 페이지 정보: 영문 111 Pages | 배송안내 : 1-2일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

플라스미드 DNA 제조 시장 특징은 다양한 치료 용도에 사용되는 플라스미드 DNA 생산에 중요한 역할을 한다는 점입니다. 플라스미드 DNA 제조 시장은 2024-2032년의 예측 기간 중 CAGR 21%로 성장할 것으로 예상됩니다. 주요 기업이 채택한 지속적인 추진력과 혁신적인 전략은 플라스미드 DNA 제조의 전망을 형성하고 첨단 유전자 치료 및 맞춤형 의료 솔루션 개발에 기여할 것으로 예상됩니다.

유전자 치료의 발전: 플라스미드 DNA 용도의 선구적 혁신

플라스미드 DNA 제조 시장은 플라스미드 DNA 응용의 선구적인 혁신으로 대표되는 유전자 치료의 끊임없는 발전에 힘입어 성장하고 있습니다. 다양한 유전성 질환 및 만성질환을 표적으로 하는 최첨단 유전자 치료에 플라스미드 DNA가 성공적으로 통합되고 있는 것이 그 증거입니다. 이러한 원동력은 플라스미드 DNA가 새로운 치료법 개발에 있으며, 매우 중요한 역할을 하는 유전자 기반 치료법의 전망이 확대되면서 더욱 강조되고 있습니다. 플라스미드 DNA 기반 치료제의 임상시험 및 승인 건수 증가에서 알 수 있듯이, 이러한 촉진요인은 2023-2032년 시장 성장에 큰 기여를 할 것으로 예상됩니다.

바이오 의약품 연구개발 투자 증가: 고품질 플라스미드 DNA 수요 증가

플라스미드 DNA 제조 시장은 바이오의약품 연구개발(R&D)에 대한 투자 증가로 인해 강력한 성장세를 보이고 있습니다. 그 증거로 바이오의약품 분야의 자금 조달과 공동연구가 증가하면서 전임상 및 임상시험용 고품질 플라스미드 DNA에 대한 수요가 급증하고 있습니다. 이러한 원동력은 유전자 치료제, 백신 및 기타 바이오 의약품 개발에서 플라스미드 DNA가 매우 중요한 역할을 하고 있으므로 더욱 강조되고 있습니다. R&D 활동과 파트너십이 크게 증가한 것에서 알 수 있듯이, 바이오 의약품 혁신에 대한 지속적인 투자로 인해 시장은 큰 혜택을 누릴 준비가 되어 있습니다.

맞춤형 의료에 대한 중요성 증대: 표적 치료를 위한 맞춤형 플라스미드 DNA 솔루션

플라스미드 DNA 생산 시장은 맞춤형 의료에 대한 관심이 높아지면서 패러다임의 변화를 목격하고 있습니다. 이는 환자 개개인프로파일에 맞게 치료적 개입을 조정하는 것에 대한 관심이 높아지면서 맞춤형 플라스미드 DNA 솔루션 생산에 대한 요구가 증가하고 있다는 증거입니다. 이러한 원동력은 정밀의료 분야에서 플라스미드 DNA의 적용이 확대되면서 더욱 강화된 효능과 안전성 프로파일을 가진 표적 치료제를 개발할 수 있는 원동력이 되고 있습니다. 맞춤의료에 대한 관심이 높아짐에 따라 맞춤치료 전략의 특정 요구사항을 충족시키기 위해 플라스미드 DNA 생산에 대한 수요가 급증할 것으로 예상됩니다.

규제 이슈와 컴플라이언스: 복잡한 규제 상황에 대한 대응

플라스미드 DNA 생산 시장의 가장 큰 억제요인은 규제 문제와 컴플라이언스 문제입니다. 치료용 플라스미드 DNA 생산 및 품질 관리에 대한 엄격한 규제가 그 증거입니다. 규제 당국이 설정한 가이드라인을 준수하고 제조업체가 복잡한 규제 상황을 헤쳐나가야 한다는 점이 이러한 제약 요인을 더욱 부각시키고 있습니다. 규제 불확실성과 새로운 컴플라이언스 기준의 등장으로 인해 시장 관계자들이 어려움을 겪고 있으며, 제품 개발 속도와 시장 침투에 영향을 미치고 있는 것이 그 증거입니다. 이러한 제약을 극복하기 위해서는 탄탄한 품질 관리 시스템을 구축하고 진화하는 규제 요건을 따라잡기 위한 적극적인 접근이 필요합니다.

등급별: 플라스미드 DNA 생산 시장이 시장을 독식

2023년, 플라스미드 DNA 제조 시장은 GMP 등급 부문에서 큰 매출을 창출했으며, 이는 엄격한 GMP 표준을 충족하는 플라스미드 DNA에 대한 수요를 반영합니다. 동시에 2024-2032년의 예측 기간 중 가장 높은 CAGR을 기록한 것은 R&D 등급 부문으로, 고품질 플라스미드 DNA를 필요로 하는 연구 활동에 중점을 두고 있음을 보여줍니다. 이러한 미묘한 세분화는 각기 다른 등급의 플라스미드 DNA의 다양한 용도를 반영하며, 각 등급은 특정 산업 요구 사항과 품질 표준을 충족합니다.

개발 단계별: 플라스미드 DNA 생산 시장이 시장을 독점

플라스미드 DNA 제조 시장은 2023년 임상 치료제 부문에서 두드러진 매출을 기록할 것으로 예상되며, 이는 임상 단계의 치료를 진행하는 데 있으며, 플라스미드 DNA가 매우 중요한 역할을 하고 있음을 강조하고 있습니다. 동시에 예측 기간 중 가장 높은 CAGR을 기록한 것은 전임상 치료제 부문으로, R&D 활동이 급증하고 있는 것으로 나타났습니다. 이러한 종합적인 세분화는 다양한 개발 단계에서 플라스미드 DNA 용도의 역동적인 특성을 보여주며, 각 단계는 전체 시장 성장에 고유한 기여를 하고 있습니다.

북미, 세계 리더의 지위를 유지

2023년 플라스미드 DNA 제조 시장은 지역적 다양성을 보였으나, 북미가 매출과 CAGR로 가장 높은 성장률을 기록했습니다. 이는 이 지역의 바이오 의약품 연구개발의 우위와 혁신적인 유전자 치료 구상의 거점으로서의 역할을 반영합니다. 유럽은 견고한 바이오테크놀러지 상황과 맞춤형 의료에 대한 투자 증가로 인해 매출에 큰 기여를 했습니다. 아시아태평양은 신흥 지역이지만, 공동 연구 증가와 바이오 의약품 발전에 대한 관심 증가에 힘입어 플라스미드 DNA 생산에 대한 안정적인 수요를 유지하고 있습니다. 이러한 지역적 추세는 플라스미드 DNA 제조 시장의 세계 특성을 강조하며, 다양한 지역이 시장 확대와 발전에 중요한 역할을 하고 있습니다.

예측 기간 중 격화하는 시장 경쟁

경쟁 구도에서는 Lonza Group, Fujifilm Holdings Corporation, Aldevron LLC, Charles River Laboratories, VGXI, Inc., Danaher(Aldevron), Kaneka Corp., Nature Technology, Cell and Gene Therapy Catapult, Eurofins Genomics, Luminous BioSciences, LLC, Akron Biotech 등의 주요 기업이 풍부한 전문성과 전략적 접근으로 시장을 형성하고 있습니다. 시장을 형성하고 있습니다. 이들 주요 기업은 2023년에 상당한 매출을 기록할 것으로 예상되며, 2024-2032년 지속적인 성장이 예상됩니다. 유전자 치료의 진화하는 요구에 대응하고, 생산 능력을 확장하고, 규제 상황을 준수하는 데 전략적으로 집중함으로써 이들 기업은 플라스미드 DNA 제조 전망에서 영향력 있는 존재로 자리매김하고 있습니다. 시장이 발전함에 따라 이들 업체들은 기술 발전에 있으며, 매우 중요한 역할을 할 것으로 예상되며, 치료용 고품질 플라스미드 DNA의 원활한 생산에 기여할 것으로 예상됩니다.

서론
세계의 플라스미드 DNA 제조 시장 금액, 2022-2032년
시장 역학
- 시장 촉진요인
- 시장 억제요인
- 주요 과제
- 주요 기회
촉진요인과 억제요인의 영향 분석
시소 분석
Porter's Five Forces 모델
- 공급업체 파워
- 바이어 파워
- 대체품의 위협
- 신규 진출업체의 위협
- 경쟁 기업간 경쟁 관계
PESTEL 분석
- 정치적 상황
- 경제 상황
- 테크놀러지 상황
- 법적 상황
- 사회적 상황

제5장 플라스미드 DNA 제조 시장 : 등급별, 2022-2032년

시장 개요
성장·매출 분석 : 2023 vs 2032
볼륨과 가격 분석, 2022-2032년
시장 세분화
- 연구개발 등급
- GMP 등급

제6장 플라스미드 DNA 제조 시장 : 개발 단계별, 2022-2032년

시장 개요
성장·매출 분석 : 2023 vs 2032
볼륨과 가격 분석, 2022-2032년
시장 세분화
- 전임상 요법
- 임상 치료학
- 시판 치료제

제7장 플라스미드 DNA 제조 시장 : 용도별, 2022-2032년

시장 개요
성장·매출 분석 : 2023 vs 2032
볼륨과 가격 분석, 2022-2032년
시장 세분화
- DNA 백신
- 세포·유전자 치료
- 면역치료
- 기타

제8장 플라스미드 DNA 제조 시장 : 질환별, 2022-2032년

시장 개요
성장·매출 분석 : 2023 vs 2032
볼륨과 가격 분석, 2022-2032년
시장 세분화
- 감염증
- 암
- 유전성 질환
- 기타

제9장 북미의 플라스미드 DNA 제조 시장, 2022-2032년

시장 개요
플라스미드 DNA 제조 시장 : 등급별, 2022-2032년
플라스미드 DNA 제조 시장 : 개발 단계별, 2022-2032년
플라스미드 DNA 제조 시장 : 용도별, 2022-2032년
플라스미드 DNA 제조 시장 : 질환별, 2022-2032년
플라스미드 DNA 제조 시장 : 지역별, 2022-2032년
- 북미
  - 미국
  - 캐나다
  - 기타 북미 지역

제10장 영국과 유럽연합의 플라스미드 DNA 제조 시장, 2022-2032년

시장 개요
플라스미드 DNA 제조 시장 : 등급별, 2022-2032년
플라스미드 DNA 제조 시장 : 개발 단계별, 2022-2032년
플라스미드 DNA 제조 시장 : 용도별, 2022-2032년
플라스미드 DNA 제조 시장 : 질환별, 2022-2032년
플라스미드 DNA 제조 시장 : 지역별, 2022-2032년
- 영국과 유럽연합
  - 영국
  - 독일
  - 스페인
  - 이탈리아
  - 프랑스
  - 기타 유럽 지역

제11장 아시아태평양의 플라스미드 DNA 제조 시장, 2022-2032년

시장 개요
플라스미드 DNA 제조 시장 : 등급별, 2022-2032년
플라스미드 DNA 제조 시장 : 개발 단계별, 2022-2032년
플라스미드 DNA 제조 시장 : 용도별, 2022-2032년
플라스미드 DNA 제조 시장 : 질환별, 2022-2032년
플라스미드 DNA 제조 시장 : 지역별, 2022-2032년
- 아시아태평양
  - 중국
  - 일본
  - 인도
  - 호주
  - 한국
  - 기타 아시아태평양

제12장 라틴아메리카의 플라스미드 DNA 제조 시장, 2022-2032년

시장 개요
플라스미드 DNA 제조 시장 : 등급별, 2022-2032년
플라스미드 DNA 제조 시장 : 개발 단계별, 2022-2032년
플라스미드 DNA 제조 시장 : 용도별, 2022-2032년
플라스미드 DNA 제조 시장 : 질환별, 2022-2032년
플라스미드 DNA 제조 시장 : 지역별, 2022-2032년
- 라틴아메리카
  - 브라질
  - 멕시코
  - 기타 라틴아메리카 지역

제13장 중동 및 아프리카의 플라스미드 DNA 제조 시장, 2022-2032년

시장 개요
플라스미드 DNA 제조 시장 : 등급별, 2022-2032년
플라스미드 DNA 제조 시장 : 개발 단계별, 2022-2032년
플라스미드 DNA 제조 시장 : 용도별, 2022-2032년
플라스미드 DNA 제조 시장 : 질환별, 2022-2032년
플라스미드 DNA 제조 시장 : 지역별, 2022-2032년
- 중동 및 아프리카
  - GCC
  - 아프리카
  - 기타 중동 및 아프리카

제14장 기업 개요

Lonza Group
Fujifilm Holdings Corporation
Aldevron LLC
Charles River Laboratories
VGXI Inc.
Danaher(Aldevron)
Kaneka Corp.
Nature Technology
Cell and Gene Therapy Catapult
Eurofins Genomics
Luminous BioSciences LLC
Akron Biotech
기타 주요 기업

KSA 24.02.19

The plasmid DNA manufacturing market is characterized by its critical role in the production of plasmid DNA used in various therapeutic applications. The plasmid DNA manufacturing market is expected to grow at a CAGR of 21% during the forecast period of 2024 to 2032. The ongoing drivers and innovative strategies employed by key players are expected to shape the landscape of plasmid DNA manufacturing, contributing to the development of advanced genetic therapies and personalized medicine solutions.

Advancements in Genetic Therapies: Pioneering Innovations in Plasmid DNA Applications

The plasmid DNA manufacturing market is being propelled by continuous advancements in genetic therapies, exemplified by pioneering innovations in plasmid DNA applications. Evidence includes the successful integration of plasmid DNA in cutting-edge gene therapies targeting various genetic disorders and chronic diseases. This driver is underscored by the expanding landscape of gene-based therapeutics, with plasmid DNA serving as a crucial component in developing novel treatments. As evidenced by the growing number of clinical trials and approvals for plasmid DNA-based therapies, this driver is expected to be a primary contributor to the market's growth from 2023 to 2032.

Increasing Investments in Biopharmaceutical R&D: Fueling Demand for High-Quality Plasmid DNA

The plasmid DNA manufacturing market is experiencing robust growth due to increasing investments in biopharmaceutical research and development (R&D). Evidence includes rising funding and collaborations in the biopharmaceutical sector, leading to a surge in demand for high-quality plasmid DNA for pre-clinical and clinical studies. This driver is emphasized by the pivotal role of plasmid DNA in the development of gene therapies, vaccines, and other biopharmaceutical products. As evidenced by the substantial increase in R&D activities and partnerships, the market is poised to benefit significantly from the sustained investment in biopharmaceutical innovations.

Growing Emphasis on Personalized Medicine: Customized Plasmid DNA Solutions for Targeted Therapies

The plasmid DNA manufacturing market is witnessing a paradigm shift driven by the growing emphasis on personalized medicine. Evidence includes the increased focus on tailoring therapeutic interventions to individual patient profiles, necessitating the production of customized plasmid DNA solutions. This driver is highlighted by the expanding applications of plasmid DNA in precision medicine, enabling the development of targeted therapies with enhanced efficacy and safety profiles. As evidenced by the rising interest in personalized medicine approaches, the demand for plasmid DNA manufacturing is expected to surge, catering to the specific requirements of individualized treatment strategies.

Regulatory Challenges and Compliance: Navigating Complex Regulatory Landscape

A significant restraint in the plasmid DNA manufacturing market revolves around regulatory challenges and compliance issues. Evidences include the stringent regulations governing the production and quality control of plasmid DNA for therapeutic use. This restraint is further underscored by the need for manufacturers to navigate a complex regulatory landscape, ensuring adherence to guidelines set by regulatory authorities. The evidence also includes instances where regulatory uncertainties and evolving compliance standards pose challenges to market players, impacting the pace of product development and market penetration. Overcoming this restraint requires a proactive approach to establishing robust quality management systems and staying abreast of evolving regulatory requirements.

By Grade: Plasmid DNA Manufacturing Market Dominates the Market

In 2023, the plasmid DNA manufacturing market demonstrated substantial revenue from the GMP Grade segment, reflecting the demand for plasmid DNA meeting stringent Good Manufacturing Practice standards. Simultaneously, the highest CAGR during the forecast period from 2024 to 2032 was observed in the R&D Grade segment, indicating a robust focus on research activities requiring high-quality plasmid DNA. This nuanced segmentation reflects the diverse applications of plasmid DNA across different grades, each catering to specific industry requirements and quality standards.

By Development Phase: Plasmid DNA Manufacturing Market Dominates the Market

The plasmid DNA manufacturing market showcased noteworthy revenue from the Clinical Therapeutics segment in 2023, emphasizing the pivotal role of plasmid DNA in advancing clinical-stage therapies. Concurrently, the highest CAGR during the forecast period was recorded in the Pre-Clinical Therapeutics segment, signifying a surge in research and development activities. This comprehensive segmentation illustrates the dynamic nature of plasmid DNA applications across different development phases, with each phase contributing uniquely to the market's overall growth.

North America Remains the Global Leader

Geographically, the plasmid DNA manufacturing market exhibited diverse trends in 2023, with North America leading in revenue generation and the highest CAGR. This reflects the region's dominance in biopharmaceutical R&D and its role as a hub for innovative gene therapy initiatives. Europe also contributed significantly to revenue, driven by a robust biotechnology landscape and increasing investments in personalized medicine. Asia-Pacific, while emerging, maintained a steady demand for plasmid DNA manufacturing, fueled by growing collaborations and a rising focus on biopharmaceutical advancements. These geographic trends underscore the global nature of the plasmid DNA manufacturing market, with different regions playing crucial roles in its expansion and evolution.

Market Competition to Intensify during the Forecast Period

In the competitive landscape, top players such as Lonza Group, Fujifilm Holdings Corporation, Aldevron LLC, Charles River Laboratories, VGXI, Inc., Danaher (Aldevron), Kaneka Corp., Nature Technology, Cell and Gene Therapy Catapult, Eurofins Genomics, Luminous BioSciences, LLC and Akron Biotech are shaping the market with their extensive expertise and strategic approaches. These key players reported substantial revenues in 2023, with expectations of continued growth from 2024 to 2032. Their strategic focus on addressing the evolving needs of genetic therapies, expanding production capacities, and ensuring compliance with regulatory standards positions them as influential entities in the plasmid DNA manufacturing landscape. As the market progresses, these players are anticipated to play a pivotal role in advancing technologies and contributing to the seamless production of high-quality plasmid DNA for therapeutic applications.

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation ofPlasmid DNA Manufacturing market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Plasmid DNA Manufacturing market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Grade

R&D Grade

GMP Grade

Development Phase

Pre-Clinical Therapeutics

Clinical Therapeutics

Marketed Therapeutics

Application

DNA Vaccines

Cell & Gene Therapy

Immunotherapy

Others

Disease

Infectious Disease

Cancer

Genetic Disorder

Others

Region Segment (2021-2031; US$ Million)

North America
- U.S.
- Canada
- Rest of North America

UK and European Union
- UK
- Germany
- Spain
- Italy
- France
- Rest of Europe

Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific

Latin America
- Brazil
- Mexico
- Rest of Latin America

Middle East and Africa
- GCC
- Africa
- Rest of Middle East and Africa

Key questions answered in this report:

What are the key micro and macro environmental factors that are impacting the growth of Plasmid DNA Manufacturing market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2031.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Plasmid DNA Manufacturing market?

Which is the largest regional market for Plasmid DNA Manufacturing market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Plasmid DNA Manufacturing market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Plasmid DNA Manufacturing market worldwide?

1. Preface

1.1. Report Description
- 1.1.1. Purpose of the Report
- 1.1.2. Target Audience
- 1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
- 1.3.1. Phase I - Secondary Research
- 1.3.2. Phase II - Primary Research
- 1.3.3. Phase III - Expert Panel Review
- 1.3.4. Assumptions
- 1.3.5. Approach Adopted

2. Executive Summary

2.1. Market Snapshot: Global Plasmid DNA Manufacturing Market
2.2. Global Plasmid DNA Manufacturing Market, By Grade, 2023 (US$ Million)
2.3. Global Plasmid DNA Manufacturing Market, By Development Phase, 2023 (US$ Million)
2.4. Global Plasmid DNA Manufacturing Market, By Application, 2023 (US$ Million)
2.5. Global Plasmid DNA Manufacturing Market, By Disease, 2023 (US$ Million)
2.6. Global Plasmid DNA Manufacturing Market, By Geography, 2023 (US$ Million)
2.7. Attractive Investment Proposition by Geography, 2023

3. Plasmid DNA Manufacturing Market: Competitive Analysis

3.1. Market Positioning of Key Plasmid DNA Manufacturing Market Vendors
3.2. Strategies Adopted by Plasmid DNA Manufacturing Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2023 Versus 2032

4. Plasmid DNA Manufacturing Market: Macro Analysis & Market Dynamics

4.1. Introduction
4.2. Global Plasmid DNA Manufacturing Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
- 4.3.1. Market Drivers
- 4.3.2. Market Restraints
- 4.3.3. Key Challenges
- 4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
- 4.6.1. Supplier Power
- 4.6.2. Buyer Power
- 4.6.3. Threat Of Substitutes
- 4.6.4. Threat Of New Entrants
- 4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
- 4.7.1. Political Landscape
- 4.7.2. Economic Landscape
- 4.7.3. Technology Landscape
- 4.7.4. Legal Landscape
- 4.7.5. Social Landscape

5. Plasmid DNA Manufacturing Market: By Grade, 2022-2032, USD (Million)

5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Volume and Pricing Analysis, 2022-2032
5.4. Market Segmentation
- 5.4.1. R&D Grade
- 5.4.2. GMP Grade

6. Plasmid DNA Manufacturing Market: By Development Phase, 2022-2032, USD (Million)

6.1. Market Overview
6.2. Growth & Revenue Analysis: 2023 Versus 2032
6.3. Volume and Pricing Analysis, 2022-2032
6.4. Market Segmentation
- 6.4.1. Pre-Clinical Therapeutics
- 6.4.2. Clinical Therapeutics
- 6.4.3. Marketed Therapeutics

7. Plasmid DNA Manufacturing Market: By Application, 2022-2032, USD (Million)

7.1. Market Overview
7.2. Growth & Revenue Analysis: 2023 Versus 2032
7.3. Volume and Pricing Analysis, 2022-2032
7.4. Market Segmentation
- 7.4.1. DNA Vaccines
- 7.4.2. Cell & Gene Therapy
- 7.4.3. Immunotherapy
- 7.4.4. Others

8. Plasmid DNA Manufacturing Market: By Disease, 2022-2032, USD (Million)

8.1. Market Overview
8.2. Growth & Revenue Analysis: 2023 Versus 2032
8.3. Volume and Pricing Analysis, 2022-2032
8.4. Market Segmentation
- 8.4.1. Infectious Disease
- 8.4.2. Cancer
- 8.4.3. Genetic Disorder
- 8.4.4. Others

9. North America Plasmid DNA Manufacturing Market, 2022-2032, USD (Million)

9.1. Market Overview
9.2. Plasmid DNA Manufacturing Market: By Grade, 2022-2032, USD (Million)
9.3. Plasmid DNA Manufacturing Market: By Development Phase, 2022-2032, USD (Million)
9.4. Plasmid DNA Manufacturing Market: By Application, 2022-2032, USD (Million)
9.5. Plasmid DNA Manufacturing Market: By Disease, 2022-2032, USD (Million)
9.6.Plasmid DNA Manufacturing Market: By Region, 2022-2032, USD (Million)
- 9.6.1.North America
  - 9.6.1.1. U.S.
    - 9.6.1.1.1. Plasmid DNA Manufacturing Market: By Grade, 2022-2032, USD (Million)
    - 9.6.1.1.2. Plasmid DNA Manufacturing Market: By Development Phase, 2022-2032, USD (Million)
    - 9.6.1.1.3. Plasmid DNA Manufacturing Market: By Application, 2022-2032, USD (Million)
    - 9.6.1.1.4. Plasmid DNA Manufacturing Market: By Disease, 2022-2032, USD (Million)
  - 9.6.1.2. Canada
    - 9.6.1.2.1. Plasmid DNA Manufacturing Market: By Grade, 2022-2032, USD (Million)
    - 9.6.1.2.2. Plasmid DNA Manufacturing Market: By Development Phase, 2022-2032, USD (Million)
    - 9.6.1.2.3. Plasmid DNA Manufacturing Market: By Application, 2022-2032, USD (Million)
    - 9.6.1.2.4. Plasmid DNA Manufacturing Market: By Disease, 2022-2032, USD (Million)
  - 9.6.1.3. Rest of North America
    - 9.6.1.3.1. Plasmid DNA Manufacturing Market: By Grade, 2022-2032, USD (Million)
    - 9.6.1.3.2. Plasmid DNA Manufacturing Market: By Development Phase, 2022-2032, USD (Million)
    - 9.6.1.3.3. Plasmid DNA Manufacturing Market: By Application, 2022-2032, USD (Million)
    - 9.6.1.3.4. Plasmid DNA Manufacturing Market: By Disease, 2022-2032, USD (Million)

10. UK and European Union Plasmid DNA Manufacturing Market, 2022-2032, USD (Million)

10.1. Market Overview
10.2. Plasmid DNA Manufacturing Market: By Grade, 2022-2032, USD (Million)
10.3. Plasmid DNA Manufacturing Market: By Development Phase, 2022-2032, USD (Million)
10.4. Plasmid DNA Manufacturing Market: By Application, 2022-2032, USD (Million)
10.5. Plasmid DNA Manufacturing Market: By Disease, 2022-2032, USD (Million)
10.6.Plasmid DNA Manufacturing Market: By Region, 2022-2032, USD (Million)
- 10.6.1.UK and European Union
  - 10.6.1.1. UK
    - 10.6.1.1.1. Plasmid DNA Manufacturing Market: By Grade, 2022-2032, USD (Million)
    - 10.6.1.1.2. Plasmid DNA Manufacturing Market: By Development Phase, 2022-2032, USD (Million)
    - 10.6.1.1.3. Plasmid DNA Manufacturing Market: By Application, 2022-2032, USD (Million)
    - 10.6.1.1.4. Plasmid DNA Manufacturing Market: By Disease, 2022-2032, USD (Million)
  - 10.6.1.2. Germany
    - 10.6.1.2.1. Plasmid DNA Manufacturing Market: By Grade, 2022-2032, USD (Million)
    - 10.6.1.2.2. Plasmid DNA Manufacturing Market: By Development Phase, 2022-2032, USD (Million)
    - 10.6.1.2.3. Plasmid DNA Manufacturing Market: By Application, 2022-2032, USD (Million)
    - 10.6.1.2.4. Plasmid DNA Manufacturing Market: By Disease, 2022-2032, USD (Million)
  - 10.6.1.3. Spain
    - 10.6.1.3.1. Plasmid DNA Manufacturing Market: By Grade, 2022-2032, USD (Million)
    - 10.6.1.3.2. Plasmid DNA Manufacturing Market: By Development Phase, 2022-2032, USD (Million)
    - 10.6.1.3.3. Plasmid DNA Manufacturing Market: By Application, 2022-2032, USD (Million)
    - 10.6.1.3.4. Plasmid DNA Manufacturing Market: By Disease, 2022-2032, USD (Million)
  - 10.6.1.4. Italy
    - 10.6.1.4.1. Plasmid DNA Manufacturing Market: By Grade, 2022-2032, USD (Million)
    - 10.6.1.4.2. Plasmid DNA Manufacturing Market: By Development Phase, 2022-2032, USD (Million)
    - 10.6.1.4.3. Plasmid DNA Manufacturing Market: By Application, 2022-2032, USD (Million)
    - 10.6.1.4.4. Plasmid DNA Manufacturing Market: By Disease, 2022-2032, USD (Million)
  - 10.6.1.5. France
    - 10.6.1.5.1. Plasmid DNA Manufacturing Market: By Grade, 2022-2032, USD (Million)
    - 10.6.1.5.2. Plasmid DNA Manufacturing Market: By Development Phase, 2022-2032, USD (Million)
    - 10.6.1.5.3. Plasmid DNA Manufacturing Market: By Application, 2022-2032, USD (Million)
    - 10.6.1.5.4. Plasmid DNA Manufacturing Market: By Disease, 2022-2032, USD (Million)
  - 10.6.1.6. Rest of Europe
    - 10.6.1.6.1. Plasmid DNA Manufacturing Market: By Grade, 2022-2032, USD (Million)
    - 10.6.1.6.2. Plasmid DNA Manufacturing Market: By Development Phase, 2022-2032, USD (Million)
    - 10.6.1.6.3. Plasmid DNA Manufacturing Market: By Application, 2022-2032, USD (Million)
    - 10.6.1.6.4. Plasmid DNA Manufacturing Market: By Disease, 2022-2032, USD (Million)

11. Asia Pacific Plasmid DNA Manufacturing Market, 2022-2032, USD (Million)

11.1. Market Overview
11.2. Plasmid DNA Manufacturing Market: By Grade, 2022-2032, USD (Million)
11.3. Plasmid DNA Manufacturing Market: By Development Phase, 2022-2032, USD (Million)
11.4. Plasmid DNA Manufacturing Market: By Application, 2022-2032, USD (Million)
11.5. Plasmid DNA Manufacturing Market: By Disease, 2022-2032, USD (Million)
11.6.Plasmid DNA Manufacturing Market: By Region, 2022-2032, USD (Million)
- 11.6.1.Asia Pacific
  - 11.6.1.1. China
    - 11.6.1.1.1. Plasmid DNA Manufacturing Market: By Grade, 2022-2032, USD (Million)
    - 11.6.1.1.2. Plasmid DNA Manufacturing Market: By Development Phase, 2022-2032, USD (Million)
    - 11.6.1.1.3. Plasmid DNA Manufacturing Market: By Application, 2022-2032, USD (Million)
    - 11.6.1.1.4. Plasmid DNA Manufacturing Market: By Disease, 2022-2032, USD (Million)
  - 11.6.1.2. Japan
    - 11.6.1.2.1. Plasmid DNA Manufacturing Market: By Grade, 2022-2032, USD (Million)
    - 11.6.1.2.2. Plasmid DNA Manufacturing Market: By Development Phase, 2022-2032, USD (Million)
    - 11.6.1.2.3. Plasmid DNA Manufacturing Market: By Application, 2022-2032, USD (Million)
    - 11.6.1.2.4. Plasmid DNA Manufacturing Market: By Disease, 2022-2032, USD (Million)
  - 11.6.1.3. India
    - 11.6.1.3.1. Plasmid DNA Manufacturing Market: By Grade, 2022-2032, USD (Million)
    - 11.6.1.3.2. Plasmid DNA Manufacturing Market: By Development Phase, 2022-2032, USD (Million)
    - 11.6.1.3.3. Plasmid DNA Manufacturing Market: By Application, 2022-2032, USD (Million)
    - 11.6.1.3.4. Plasmid DNA Manufacturing Market: By Disease, 2022-2032, USD (Million)
  - 11.6.1.4. Australia
    - 11.6.1.4.1. Plasmid DNA Manufacturing Market: By Grade, 2022-2032, USD (Million)
    - 11.6.1.4.2. Plasmid DNA Manufacturing Market: By Development Phase, 2022-2032, USD (Million)
    - 11.6.1.4.3. Plasmid DNA Manufacturing Market: By Application, 2022-2032, USD (Million)
    - 11.6.1.4.4. Plasmid DNA Manufacturing Market: By Disease, 2022-2032, USD (Million)
  - 11.6.1.5. South Korea
    - 11.6.1.5.1. Plasmid DNA Manufacturing Market: By Grade, 2022-2032, USD (Million)
    - 11.6.1.5.2. Plasmid DNA Manufacturing Market: By Development Phase, 2022-2032, USD (Million)
    - 11.6.1.5.3. Plasmid DNA Manufacturing Market: By Application, 2022-2032, USD (Million)
    - 11.6.1.5.4. Plasmid DNA Manufacturing Market: By Disease, 2022-2032, USD (Million)
  - 11.6.1.6. Rest of Asia Pacific
    - 11.6.1.6.1. Plasmid DNA Manufacturing Market: By Grade, 2022-2032, USD (Million)
    - 11.6.1.6.2. Plasmid DNA Manufacturing Market: By Development Phase, 2022-2032, USD (Million)
    - 11.6.1.6.3. Plasmid DNA Manufacturing Market: By Application, 2022-2032, USD (Million)
    - 11.6.1.6.4. Plasmid DNA Manufacturing Market: By Disease, 2022-2032, USD (Million)

12. Latin America Plasmid DNA Manufacturing Market, 2022-2032, USD (Million)

12.1. Market Overview
12.2. Plasmid DNA Manufacturing Market: By Grade, 2022-2032, USD (Million)
12.3. Plasmid DNA Manufacturing Market: By Development Phase, 2022-2032, USD (Million)
12.4. Plasmid DNA Manufacturing Market: By Application, 2022-2032, USD (Million)
12.5. Plasmid DNA Manufacturing Market: By Disease, 2022-2032, USD (Million)
12.6.Plasmid DNA Manufacturing Market: By Region, 2022-2032, USD (Million)
- 12.6.1.Latin America
  - 12.6.1.1. Brazil
    - 12.6.1.1.1. Plasmid DNA Manufacturing Market: By Grade, 2022-2032, USD (Million)
    - 12.6.1.1.2. Plasmid DNA Manufacturing Market: By Development Phase, 2022-2032, USD (Million)
    - 12.6.1.1.3. Plasmid DNA Manufacturing Market: By Application, 2022-2032, USD (Million)
    - 12.6.1.1.4. Plasmid DNA Manufacturing Market: By Disease, 2022-2032, USD (Million)
  - 12.6.1.2. Mexico
    - 12.6.1.2.1. Plasmid DNA Manufacturing Market: By Grade, 2022-2032, USD (Million)
    - 12.6.1.2.2. Plasmid DNA Manufacturing Market: By Development Phase, 2022-2032, USD (Million)
    - 12.6.1.2.3. Plasmid DNA Manufacturing Market: By Application, 2022-2032, USD (Million)
    - 12.6.1.2.4. Plasmid DNA Manufacturing Market: By Disease, 2022-2032, USD (Million)
  - 12.6.1.3. Rest of Latin America
    - 12.6.1.3.1. Plasmid DNA Manufacturing Market: By Grade, 2022-2032, USD (Million)
    - 12.6.1.3.2. Plasmid DNA Manufacturing Market: By Development Phase, 2022-2032, USD (Million)
    - 12.6.1.3.3. Plasmid DNA Manufacturing Market: By Application, 2022-2032, USD (Million)
    - 12.6.1.3.4. Plasmid DNA Manufacturing Market: By Disease, 2022-2032, USD (Million)

13. Middle East and Africa Plasmid DNA Manufacturing Market, 2022-2032, USD (Million)

13.1. Market Overview
13.2. Plasmid DNA Manufacturing Market: By Grade, 2022-2032, USD (Million)
13.3. Plasmid DNA Manufacturing Market: By Development Phase, 2022-2032, USD (Million)
13.4. Plasmid DNA Manufacturing Market: By Application, 2022-2032, USD (Million)
13.5. Plasmid DNA Manufacturing Market: By Disease, 2022-2032, USD (Million)
13.6.Plasmid DNA Manufacturing Market: By Region, 2022-2032, USD (Million)
- 13.6.1.Middle East and Africa
  - 13.6.1.1. GCC
    - 13.6.1.1.1. Plasmid DNA Manufacturing Market: By Grade, 2022-2032, USD (Million)
    - 13.6.1.1.2. Plasmid DNA Manufacturing Market: By Development Phase, 2022-2032, USD (Million)
    - 13.6.1.1.3. Plasmid DNA Manufacturing Market: By Application, 2022-2032, USD (Million)
    - 13.6.1.1.4. Plasmid DNA Manufacturing Market: By Disease, 2022-2032, USD (Million)
  - 13.6.1.2. Africa
    - 13.6.1.2.1. Plasmid DNA Manufacturing Market: By Grade, 2022-2032, USD (Million)
    - 13.6.1.2.2. Plasmid DNA Manufacturing Market: By Development Phase, 2022-2032, USD (Million)
    - 13.6.1.2.3. Plasmid DNA Manufacturing Market: By Application, 2022-2032, USD (Million)
    - 13.6.1.2.4. Plasmid DNA Manufacturing Market: By Disease, 2022-2032, USD (Million)
  - 13.6.1.3. Rest of Middle East and Africa
    - 13.6.1.3.1. Plasmid DNA Manufacturing Market: By Grade, 2022-2032, USD (Million)
    - 13.6.1.3.2. Plasmid DNA Manufacturing Market: By Development Phase, 2022-2032, USD (Million)
    - 13.6.1.3.3. Plasmid DNA Manufacturing Market: By Application, 2022-2032, USD (Million)
    - 13.6.1.3.4. Plasmid DNA Manufacturing Market: By Disease, 2022-2032, USD (Million)

14. Company Profile

14.1. Lonza Group
- 14.1.1. Company Overview
- 14.1.2. Financial Performance
- 14.1.3. Product Portfolio
- 14.1.4. Strategic Initiatives
14.2. Fujifilm Holdings Corporation
- 14.2.1. Company Overview
- 14.2.2. Financial Performance
- 14.2.3. Product Portfolio
- 14.2.4. Strategic Initiatives
14.3. Aldevron LLC
- 14.3.1. Company Overview
- 14.3.2. Financial Performance
- 14.3.3. Product Portfolio
- 14.3.4. Strategic Initiatives
14.4. Charles River Laboratories
- 14.4.1. Company Overview
- 14.4.2. Financial Performance
- 14.4.3. Product Portfolio
- 14.4.4. Strategic Initiatives
14.5. VGXI, Inc.
- 14.5.1. Company Overview
- 14.5.2. Financial Performance
- 14.5.3. Product Portfolio
- 14.5.4. Strategic Initiatives
14.6. Danaher (Aldevron)
- 14.6.1. Company Overview
- 14.6.2. Financial Performance
- 14.6.3. Product Portfolio
- 14.6.4. Strategic Initiatives
14.7. Kaneka Corp.
- 14.7.1. Company Overview
- 14.7.2. Financial Performance
- 14.7.3. Product Portfolio
- 14.7.4. Strategic Initiatives
14.8. Nature Technology
- 14.8.1. Company Overview
- 14.8.2. Financial Performance
- 14.8.3. Product Portfolio
- 14.8.4. Strategic Initiatives
14.9. Cell and Gene Therapy Catapult
- 14.9.1. Company Overview
- 14.9.2. Financial Performance
- 14.9.3. Product Portfolio
- 14.9.4. Strategic Initiatives
14.10. Eurofins Genomics
- 14.10.1. Company Overview
- 14.10.2. Financial Performance
- 14.10.3. Product Portfolio
- 14.10.4. Strategic Initiatives
14.11. Luminous BioSciences, LLC
- 14.11.1. Company Overview
- 14.11.2. Financial Performance
- 14.11.3. Product Portfolio
- 14.11.4. Strategic Initiatives
14.12. Akron Biotech
- 14.12.1. Company Overview
- 14.12.2. Financial Performance
- 14.12.3. Product Portfolio
- 14.12.4. Strategic Initiatives
14.13. Other Notable Players
- 14.13.1. Company Overview
- 14.13.2. Financial Performance
- 14.13.3. Product Portfolio
- 14.13.4. Strategic Initiatives

02-2025-2992
(주말 및 공휴일 제외)

라이선스 / 가격

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,500

￦ 6,511,000

PDF (Multi User License)

PDF 보고서를 동일 사업장에서 10명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,500

￦ 9,404,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 9,000

￦ 13,022,000

※ 부가세 별도